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Abstract: Cancer is a major risk factor for the development of venous thromboembolism (VTE). 
Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer 
patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related 
bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with 
extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to 
be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with 
VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an 
overview of the role of dalteparin in the management of VTE in patients with cancer.
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Introduction
Cancer is a major risk factor for the development of venous thromboembolism (VTE). 
Patients with cancer have a 4- to 7-fold higher incidence of VTE than patients with-
out cancer (Heit et al 2000b; Blom et al 2005) Cancer is also a major risk factor for 
bleeding. Patients with cancer and VTE have a 2-fold higher risk of major bleeding 
while receiving anticoagulant therapy than patients with VTE who do not have cancer 
(Prandoni et al 2002). Adding further complexity to the issue, patients with cancer 
and VTE who are treated with conventional anticoagulant therapy are more likely 
to develop recurrent VTE than their non-cancer cohorts. To better balance the need 
for efﬁ  cacy with safety, anticoagulant therapy for patients with VTE and cancer has 
recently shifted away from conventional treatment to long-term therapy with the low-
molecular weight heparin, dalteparin (Fragmin®; Pﬁ  zer). This paper will (a) review 
the relationship between cancer and VTE, and (b) provide an overview of the role of 
dalteparin in the management of VTE in patients with cancer.
Cancer and venous thromboembolism
Risk
The incidence of VTE in patients with cancer has been difﬁ  cult to determine because 
of the heterogeneity of the patient population. The most recent estimates come from 
two large population-based studies which linked cancer registries to other health-
related databases (Blom et al 2006; Chew et al 2006). Blom and colleagues linked a 
Netherlands cancer registry to regional anticoagulation clinics (n = 66,329 patients) 
and reported a cumulative incidence of VTE of 24.6 per 1000 patients in the ﬁ  rst year 
following cancer diagnosis (Blom et al 2006). Chew and colleagues linked a California 
cancer registry to a state-wide patient discharge database (n = 235,149 patients) and 
reported a cumulative incidence of VTE of 16 per 1000 patients over the ﬁ  rst 2 years 
following cancer diagnosis (Chew et al 2006). Although these registries consist of a 
large number of patients, it is likely that they underestimate the incidence of VTE in Vascular Health and Risk Management 2008:4(2) 280
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patients with cancer because not all cases were reported. 
The reported incidence of VTE in smaller cancer cohort 
studies ranges from 7.8% (ie, deep vein thrombosis [DVT] 
and pulmonary embolism [PE] in patients with solid tumors) 
to 13.6% (ie, DVT only in patients with non-small cell lung 
cancer) (Sallah et al 2002; Tagalakis et al 2007).
A recent retrospective review of 435 consecutive stag-
ing CT scans performed on patients with a variety of tumor 
types reported a prevalence of clinically silent VTE of 6.3% 
(Cronin et al 2007). These data suggests that the true inci-
dence of VTE in cancer patients is likely much higher than 
indicated by any of the previous studies.
The major determinants of the risk of VTE in cancer 
patients include tumor stage, tumor type, chemotherapy, 
hormonal therapy, surgery, and presence of central venous 
catheters. Patients with metastatic cancer have at least a 2- to 
4-fold increased risk of VTE in the ﬁ  rst 6 months after cancer 
diagnosis compared to patients with limited stage cancer 
(Blom et al 2005, 2006). Chew and colleagues reported that 
the patients with metastatic cancer who have the highest inci-
dence of VTE are as follows: pancreatic cancer (20 per 100 
patient-years), stomach (10.7 per 100 patient-years), bladder 
(7.9 per 100 patient-years), uterine (6.4 per 100 patient-
years), renal (6.0 per 100 patient-years), and lung (5.0 per 
100 patient-years) (Chew et al 2006). The true incidence of 
VTE according to tumor type is controversial because of 
the heterogeneity of the population. In one report, the tumor 
types with the highest risk of VTE were bone, ovary, brain, 
and pancreas (Blom et al 2006). In the same report, it was 
noted that more cases of VTE were observed in patients with 
tumors of the breast, prostate, lung and colon, presumably 
because these types of cancer have a higher prevalence and 
a longer survival time (Blom et al 2006).
The risk of VTE in patients receiving chemotherapy is 
a moving target because of the variety of agents currently 
available as well as the ongoing introduction of new agents. 
In one retrospective review of 206 unselected cancer patients 
who received chemotherapy, the annual incidence of  VTE 
was reported to be 11% (Otten et al 2004). Similar estimates 
have been reported by other investigators for patients with 
breast cancer (von Tempelhoff et al 1996) and ovarian can-
cer (von Tempelhoff et al 1998). The risk of VTE has been 
noted to be signiﬁ  cantly higher in patients who receive a 
combination of agents. For example, the incidence of VTE 
when patients with multiple myeloma are given thalidomide 
or dexamethasone alone is increased by 2.6-fold and 2.8-fold, 
respectively. When these agents are given in combination, 
the risk of VTE rises to 8-fold (Haddad and Greeno 2006;
El Accaoui et al 2007). Similarly, the combination of 
tamoxifen with chemotherapy in the treatment of women 
with breast cancer increases the risk 3 to 5-fold higher than 
with tamoxifen alone (Deitcher and Gomes 2004).
The risk of VTE has been brought to the forefront as 
a signiﬁ  cant safety concern during evaluation of some of 
the newer antineoplastic agents. Lenalidomide, an analog 
of thalidomide, has fewer side effects than its predeces-
sor, but shares its high risk of VTE (ranging from 4% to 
75% in uncontrolled studies) (Hirsh 2007). This observa-
tion has prompted investigators of one ongoing trial to 
mandate that all study subjects in the lenalidomide-high 
dose dexamethasone arm receive prophylaxis with aspirin, 
low-molecular-weight heparin or warfarin (Rajkumar and 
Blood 2006; Zonder et al 2006). (There are no randomized 
controlled trials to support the effectiveness of aspirin in 
this setting [Hirsh 2007].) With another agent, bevacizumab 
(an angiogenesis inhibitor), initial reports suggested that the 
risk of VTE in patients was a major concern (Kabbinavar 
et al 2003; Shah et al 2005), but more recent studies have 
shown that it is likely the combination of agents, and not 
bevacizumab alone, that leads to the high rate of thrombosis 
(Herbst and Sandler 2004; Hurwitz et al 2004; Rugo 2004; 
Haddad and Greeno 2006)
Supportive agents used to treat cancer patients, such as 
erythropoietin, granulocyte colony-stimulating factor, and 
high-dose corticosteroids have also been implicated as risk fac-
tors for VTE in cancer patients (Haddad and Greeno 2006).
Surgery and the use of indwelling central venous catheters 
are risk factors for VTE in the general population. The addi-
tion of cancer under these conditions leads to a cumulative 
increase in risk. The risk of post-operative VTE in cancer 
patients who undergo surgery is at least double the risk for 
non-cancer patients who undergo the same procedure (Geerts 
et al 2004). More importantly, cancer patients who undergo 
surgery have a 3-fold higher risk of fatal PE, as conﬁ  rmed 
on autopsy, compared with non-cancer patients (Kakkar 
et al 2005).
Central venous catheters are essential for the management 
of many cancer patients, but they also increase the risk of 
upper limb venous thrombosis and pulmonary embolism. The 
incidence of symptomatic catheter-rated thrombosis had pre-
viously been reported to be as high as 28%, but more recent 
studies place the risk closer to 4% (Lee et al 2006). Risk 
factors for the development of catheter-related thrombosis in 
one prospective study included multiple insertion attempts, 
previous central venous catherization, and ovarian cancer 
(Lee et al 2006).Vascular Health and Risk Management 2008:4(2) 281
Dalteparin for treatment of cancer-associated thrombosis
The diagnosis of VTE in a cancer patient is associated 
with a poor outcome. These patients have a 2- to 4-fold 
increased risk of recurrent VTE while receiving antico-
agulant therapy as compared with non-cancer patients with 
VTE (Heit et al 2000a; Prandoni et al 2002). They also have 
2-fold higher risk of major bleeding (Prandoni et al 2002). 
Unlike non-cancer patients with VTE, most thrombotic and 
bleeding complications in patients with cancer and VTE 
occur while anticoagulant therapy is within the established 
therapeutic range (Hutten et al 2000; Prandoni et al 2002). 
Lastly, cancer patients with VTE have a higher mortality 
rate than cancer patients who do not have VTE (hazard ratio 
1.6–4.2, p   0.01) (Chew et al 2006). Mortality appears to 
be particularly high in patients who have cancer diagnosed at 
the same time as their primary VTE (ie, 1-year survival rate 
of 12% compared with 36% survival rate in patients without 
VTE who were matched for type of cancer, age, sex, and year 
of diagnosis) (Sorensen et al 2000).
Pathogenesis
Cancer promotes the development of VTE by inducing a 
hypercoaguable state. The mechanisms by which this hyper-
coaguable state is produced are complex and multifactorial. It 
has been shown that tumor cells promote activation of blood 
coagulation by: (i) producing procoagulant factors (Gale 
and Gordon 2001), (ii) releasing cytokines (Grignani and 
Maiolo 2000), and (iii) by direct cell-to-cell interaction with 
patient endothelial cells, leucocytes and platelets (Prandoni 
et al 2005; Buller et al 2007). One of the key procoagulant 
factors produced is tissue factor, the primary activator of 
normal blood coagulation. While normal endothelial cells 
only express tissue factor when stimulated, tumor cells 
constitutively express tissue factor. An increased level of 
tissue factor promotes angiogenesis, and permeability of the 
vascular endothelium to tumor cells. Another procoagulant 
factor produced by tumor cells is cancer procoagulant, a 
cysteine proteinase that activates Factor X independently 
of Factor VIIa. Cytokines produced and released by tumor 
cells include TNFα, IL-1β, and vascular endothelial growth 
factor (VEGF). TNFα and IL-1β promote thrombosis at the 
vascular wall by inducing endothelial expression of tissue 
factor and downregulating expression of thrombomodulin, 
the endothelial thrombin receptor that plays a key role 
in the activation of the anticoagulant protein C pathway. 
Increased levels of VEGF contribute to angiogenesis and 
inhibit apoptosis. Lastly, tumor cells express cell-adhesion 
molecules on their surface, which allows them to directly 
interact with endothelial cells, platelets, and leucocytes. The 
end result of the mechanisms above, and others not outlined 
in this review, is the promotion of ﬁ  brin formation. Fibrin 
formation, the ﬁ  nal step in the blood coagulation pathway, has 
been shown to support angiogenesis which, in turn, promotes 
tumor growth and metastasis (Bromberg et al 1995; Rickles 
et al 2003; Rak et al 2006).
Prevention
There is strong evidence to support the need for primary 
thromboprophylaxis in patients who undergo surgery or 
require prolonged hospitalization (Geerts et al 2004). Both 
unfractionated heparin and low-molecular-weight heparin, 
administered subcutaneously in low doses, have been shown 
to be effective and safe for thromboprophylaxis in these set-
tings in the general population (Geerts et al 2004). Although 
the majority of data for thromboprophylaxis for cancer 
patients comes from subgroup analyses of general surgery 
studies (Mismetti et al 2001; Bergqvist 2007), there are a few 
studies which restricted enrolment to cancer patients. In the 
randomized, double-blind ENOXACAN study, enoxaparin 
(Lovenox®; Sanoﬁ  -Aventis) 40 mg once-daily (started 2 hours 
pre-operatively) was compared with unfractionated heparin 
5000 units 3 times daily in 1115 high-risk patients over 40 
years of age who underwent elective curative abdominal or 
pelvic surgery for cancer (ENOXACAN Study Group 1997). 
The incidence of  VTE (on bilateral venography or pulmonary 
scintigraphy) and bleeding rates were equivalent in the two 
groups. In a smaller study, dalteparin 5000 units daily (start-
ing with a 2500 unit dose 2 hours pre-operatively and another 
12 hours postoperatively) was compared with unfractionated 
heparin 5000 units 3 times daily (starting with a dose 2 hours 
pre-operatively) in 40 patients undergoing pelvic or abdomi-
nal cancer surgery (Fricker et al 1988). Both regimens were 
found to be equally effective and safe.
The efﬁ  cacy and safety of extended duration throm-
boprophylaxis in cancer patients undergoing surgery has 
been evaluated in 4 studies to date (2 published as papers 
and 2 published in abstract form) (Rasmussen et al 2005). 
ENOXACAN II was a randomized double-blind study that 
compared 1 week of thromboprophylaxis with enoxaparin 
40 mg daily with a 4-week course of enoxaparin in patients 
undergoing elective surgery for abdominal or pelvic cancer 
surgery (Bergqvist et al 2002). The results showed a 60% 
reduction in the relative risk of venographically detected VTE 
with the 4-week course compared with the 1 week course 
(4.8% vs 12%, p = 0.02). The incidence of major bleeding was 
not signiﬁ  cantly different between the two groups. Similar 
results were reported in an open label study that compared Vascular Health and Risk Management 2008:4(2) 282
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dalteparin 5000 units once daily for 7 days with the same 
regimen for 28 days in 343 patients (200 patients with cancer) 
who underwent major abdominal surgery (Rasmussen et al 
2006). The primary outcome, venographically-detected VTE, 
occurred in 16.3% in the short-term prophylaxis arm and 
7.3% in the extended duration prophylaxis arm (relative risk 
reduction 55%, p = 0.012). Current guidelines recommend 
extended duration thromboprophylaxis of 28–35 days in can-
cer patients who undergo high-risk surgery (eg, orthopedic 
surgery) (Geerts et al 2004).
Both warfarin and low-molecular-weight heparin have 
been evaluated for primary thromboprophylaxis in patients 
with indwelling central venous catheters (Couban et al 2005; 
Verso et al 2005; Karthaus et al 2006). Neither agent was 
found to be effective at preventing symptomatic catheter-
related VTE and neither agent is currently recommended for 
this indication (Geerts et al 2004).
Management
Conventional treatment of VTE consists of 5–7 days of 
therapeutic dose heparin or low-molecular-weight hepa-
rin followed by a vitamin K antagonist for a minimum of 
3 months titrated to an international normalization ratio 
(INR) of 2.0–3.0. Unfortunately, conventional anticoagulant 
therapy in VTE patients who also have cancer tends to be 
more problematic than in non-cancer patients with VTE. 
For example, the long half-life of vitamin K antagonists cre-
ates management difﬁ  culties in cancer patients who require 
frequent invasive procedures (eg, therapeutic paracentesis) 
and develop chemotherapy-induced thrombocytopenia. 
Cancer patients also tend to have poor appetites and take 
multiple medications, both of which lead to erratic INRs 
and difﬁ  culties with warfarin dosing. Finally, cancer patients 
who require frequent needle sticks for the administration of 
chemotherapy, also tend to have poor venous access, which 
can make INR monitoring in the community a challenge 
(Lee and Levine 2003).
Recently, studies have shown that extended duration 
low-molecular-weight heparin is an effective and safe 
alternative to conventional anticoagulant therapy in cancer 
patients with VTE. The ﬁ  rst published study was CANTHA-
NOX, an open-label comparison of 3 months of warfarin 
with enoxaparin in 146 cancer patients with proximal DVT, 
PE, or both (Meyer et al 2002). This trial was terminated 
early due to poor recruitment. The investigators reported 
no signiﬁ  cant difference in the incidence of the primary 
outcome, a combined endpoint of major bleeding or recur-
rent VTE within 3 months.
The second study was LITE, a randomized multicentre 
trial that compared warfarin with tinzaparin (Innohep®; Leo 
Pharma) in 737 patients with proximal DVT (200 patients 
had cancer). (Hull et al 2006) After 12 weeks of treatment, 
recurrent VTE occurred in 10% of the cancer patients who 
received warfarin, and 6% of the cancer patients who received 
tinzaparin. One year after randomization, 16% of cancer 
patients who received warfarin had recurrent VTE, in com-
parison with 7% of cancer patients who received tinzaparin 
(p = 0.044). There was no signiﬁ  cant difference between the 
groups with respect to bleeding (7% major bleeds in both 
groups) or mortality (19% mortality in warfarin group versus 
20% mortality in tinzaparin group) at 3 months.
The third study was ONCENOX, an open-label com-
parison of warfarin with two different doses of enoxaparin 
in 101 cancer patients with acute VTE (Deitcher et al 2006). 
This trial was terminated early due to poor recruitment. After 
6 months of treatment, recurrent VTE occurred in 10.3% 
of patients who received warfarin, 6.9% of patients who 
received low-dose enoxaparin, and 6.3% of patients who 
received higher-dose enoxaparin. Major bleeding occurred 
in 2.9% of patients who received warfarin, 6.5% of patients 
who received low-dose enoxaparin, and 11.1% of patients 
who received high-dose enoxaparin (p = not signiﬁ  cant). 
The mortality rate was 32.4% of patients who received war-
farin, 22.6% of patients who received low-dose enoxaparin, 
and 41.7% of patients who received high-dose enoxaparin 
(p = not signiﬁ  cant).
Early termination of both the CANTHANOX and 
ONCENOX trials means that neither study was powered to 
show a signiﬁ  cant difference in efﬁ  cacy or safety between 
warfarin and low-molecular-weight heparin in cancer 
patients. Poor recruitment into these studies, possibly due 
to the requirement for injections, suggested that adequately 
powered trials to study this issue might not be possible. 
However, two further studies evaluating extended duration 
low-molecular-weight heparin (dalteparin) for treatment of 
cancer-related VTE were successfully completed and will 
be discussed in detail later in this review (Lee et al 2003; 
Monreal et al 2004).
The duration of anticoagulant therapy in cancer patients 
with VTE is also problematic. It is generally accepted that 
patients with metastatic cancer should remain on anticoagu-
lants indeﬁ  nitely, unless they develop bleeding complications 
or request discontinuation for quality-of-life reasons. 
However, the appropriate duration of anticoagulant therapy 
in patients with limited stage cancer (I or II) who develop 
VTE is unknown. If the malignancy is in remission, and other Vascular Health and Risk Management 2008:4(2) 283
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risk factors have resolved (eg, immobility, chemotherapy, 
surgery), it is likely safe to discontinue anticoagulants after 
a minimum of 3 months of treatment. However, this strategy 
has never been evaluated in a clinical trial, and there is always 
the risk that recurrent VTE might be the ﬁ  rst clinical sign of 
return of the malignancy.
Role of dalteparin in the management 
of venous thromboembolism 
in cancer patients
Pharmacology and pharmacokinetics
Dalteparin sodium (Fragmin®; Pﬁ  zer) is a low-molecular-weight 
heparin that consists of strongly acidic sulphated polysac-
charide chains with a mean molecular weight of 5000 Da 
(range 2000–9000 Da). It is derived from pork intestinal 
mucosal heparin (molecular weight 3000–30,000 Da) by 
partial nitrous acid depolymerization (Fareed et al 2004). 
Similar to unfractionated heparin, dalteparin contains the 
pentasaccharide sequence that is responsible for its ability 
to bind to antithrombin. In contrast to unfractionated hepa-
rin, the majority of dalteparin chains do not contain the 18 
saccharide sequence that is required to simultaneously bind 
to antithrombin and thrombin. Consequently, dalteparin is 
able to induce the conformational change in antithrombin 
that enhances its ability to inhibit activated coagulation fac-
tors Xa (also IXa, XIa, XIIa), but it is not able to enhance 
antithrombin-dependent inhibition of thrombin (ie, reduced 
anti-IIa/anti-Xa ratio). The anticoagulant effect of dalteparin 
is, by convention, expressed in terms of its anti-Xa activity 
(international standard units [IU] per kg). The speciﬁ  c activity 
of dalteparin on factor Xa is 130 IU/mg and on thrombin is 
58 IU/mg therefore the anti-IIa/anti-Xa ratio for dalteparin 
is 2.2 (Anonymous 2006).
The goal for the development of dalteparin and the 
other low-molecular-weight heparins was to overcome 
the pharmacokinetic limitations of unfractionated heparin 
(referred to as heparin for the remainder of this review) 
(Hirsh and Raschke 2004). Firstly, heparin binds to plasma 
proteins, which produces an unpredictable anticoagulant 
response, and makes laboratory monitoring necessary when 
it is given intravenously. Secondly, it has poor subcutane-
ous bioavailability (20%–30%) and a short half-life which 
means it must be administered twice daily when given by 
subcutaneous injection. Finally, heparin binds to platelet 
factor IV (PF4) which reduces its anticoagulant effect, and 
can lead to the development of heparin-induced thrombo-
cytopenia (HIT).
In contrast, dalteparin does not bind to plasma proteins, 
has excellent bioavailability (87%) when given by subcutane-
ous injection (Bratt et al 1986), and produces a predictable 
anticoagulant response (Hirsh and Raschke 2004). HIT 
has been reported in patients who received dalteparin, but 
the incidence is estimated at 1% versus 12% with heparin 
(Levine et al 2006).
Dalteparin exhibits dose-independent ﬁ  rst order pharma-
cokinetics (Dunn and Jarvis 2000). The rate-limiting step after 
subcutaneous injection is absorption (Bratt et al 1986). Peak 
plasma concentrations are reached 3–5 hours after subcutane-
ous injection (Handeland et al 1990). The volume of distribu-
tion in healthy volunteers was 7.7–9 L (Collignon et al 1995). 
The plasma elimination half-life is 3–4 hours (Simoneau et al 
1992; Collignon et al 1995) The principle route of elimination 
of dalteparin is renal. The product monograph for dalteparin 
currently recommends monitoring and dose adjustment for 
patients with renal insufﬁ  ciency (especially for patients with 
a creatinine clearance of less than 30 mL/min) due to concern 
about prolongation of anti-Xa activity. However, a recent pilot 
study has shown that when given in prophylactic doses (5000 
units daily) to intensive care unit patients with renal insuf-
ﬁ  ciency, peak anti-Xa levels remained within the conventional 
prophylactic range (Rabbat et al 2005). Monitoring of anti-Xa 
levels in standard risk patients who are given body-weight 
adjusted doses of dalteparin is not necessary (Alhenc-Gelas 
et al 1994; Boneu and de Moerloose 2001; Hirsh and Raschke 
2004). A substudy of cancer patients who received extended 
duration dalteparin at therapeutic doses to treat VTE did not 
show any evidence of bioaccumulation after one month of 
treatment (Kovacs et al 2005).
Treatment of venous thromboembolism
Subcutaneous dalteparin has been compared with heparin for 
initial treatment of VTE in multiple randomized trials (Holm 
et al 1986; Harenberg et al 1990; Lindmarker et al 1994; Meyer 
et al 1995; Fiessinger et al 1996; Luomanmaki et al 1996; 
Kearon et al 2006). The consensus is that dalteparin and the 
other low-molecular-weight heparins are safe and effective 
as conventional anticoagulant therapy for treatment of acute 
VTE (Leizorovicz et al 1994; Gould et al 1999; Quinlan et al 
2004). Only one head-to-head trial comparing dalteparin with 
another low-molecular-weight heparin has been conducted in 
this patient population. Wells and colleagues randomized 254 
patients with acute VTE to receive either dalteparin 200 IU/kg 
or tinzaparin 175 IU/kg for a minimum of 5 days followed 
by a vitamin antagonist for 3 months (Wells et al 2005). The 
primary outcome, a composite of recurrent VTE and bleeding, Vascular Health and Risk Management 2008:4(2) 284
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occurred in 4.4% of the patients who received dalteparin and 
5.9% of the patients who received tinzaparin (p = 0.44).
Treatment of venous thromboembolism 
in cancer patients
Two clinical trials and one case series evaluating extended 
duration dalteparin for treatment of VTE in cancer patients 
have been published to date.
CLOT
The CLOT study was a 676 patient open-label trial that 
randomized cancer patients with acute DVT, PE, or both 
to conventional anticoagulant therapy or extended duration 
dalteparin (Lee et al 2003). Patients in the conventional 
treatment arm were given 5–7 days of dalteparin 200 IU/kg 
(maximum 18,000 IU) by once-daily subcutaneous injec-
tion followed by a vitamin K antagonist for 6 months (INR 
2.0–3.0). Patients in the extended duration dalteparin arm 
were given dalteparin 200 IU/kg (maximum 18,000 IU) by 
once-daily subcutaneous injection for the ﬁ  rst 4 weeks fol-
lowed by dalteparin 150 IU/kg for the remaining 5 months.
The primary outcome measure, symptomatic recur-
rent VTE at 6 months, occurred in 27 patients (8%) in the 
extended duration dalteparin arm, and 53 patients (15.8%) in 
the conventional treatment arm (relative risk reduction 52%; 
p = 0.002). There were 5 fatal PEs in the extended duration 
dalteparin arm, and 7 fatal PEs in the conventional treatment 
arm. The majority of recurrent VTE in the conventional 
treatment arm occurred when the INR was within or above 
the therapeutic range.
Major bleeding occurred in 19 patients (6%) in the 
extended duration dalteparin arm and 12 patients (4%) in the 
conventional treatment arm (p = 0.27). There was 1 fatal bleed 
in the extended duration dalteparin arm and no fatal bleeds 
in the conventional treatment arm. At the time of a major 
bleeding event, 2 patients in the extended duration dalteparin 
arm had thrombocytopenia, and 6 patients in the conventional 
treatment arm had an INR greater than 3.0. The overall mortal-
ity rate did not differ signiﬁ  cantly between the two groups. The 
authors concluded that extended duration dalteparin was more 
effective, and as safe as conventional anticoagulant therapy 
for patients with cancer and acute VTE. A comparison of the 
properties of warfarin with extended duration dalteparin for 
long-term anticoagulation is given in Table 1.
Monreal cohort study
The second trial was a prospective cohort study of 203 
patients with metastatic cancer and symptomatic VTE 
(Monreal et al 2004). Patients received dalteparin 200 IU/kg 
subcutaneously once daily for 7 days followed by a ﬁ  xed 
dose of dalteparin 10,000 IU once daily for at least 3 months. 
During the 3 month study period, 11 patients (5.4%) devel-
oped major bleeding complications, 6 of which were fatal. 
Recurrent VTE occurred in 21 patients (10.3%), 2 of which 
were fatal PEs. Three patients with recurrent VTE had their 
thrombotic event shortly after adjustment of their dalteparin 
dose in response to a bleeding event. The authors concluded 
that ﬁ  xed dose dalteparin for 3 months does not increase 
bleeding in cancer patients with acute VTE and liver or 
brain metastases.
Noble case series
Noble and colleagues reported on a case series of 62 palliative 
care cancer patients who received dalteparin for treatment of 
VTE (Noble et al 2007). None of the patients in this series 
were receiving active antineoplastic treatment at the time 
of treatment of their VTE, and 95% had metastatic disease 
(the remaining 5% had incurable primary brain malignancy). 
ECOG status and life expectancy were not reported. Dalteparin 
was given to the patients according to either the CLOT study 
Table 1 Comparison of warfarin with dalteparin for long-term anticoagulation
Warfarin  Extended duration dalteparin
•  oral agent  •  once or twice daily subcutaneous injections
•  delayed onset of anticoagulant effect  •  rapid onset of anticoagulant effect
•  mean plasma half-life: 40 hours  •  mean plasma half-life: 4 hours
•  prolonged anticoagulant effect with hepatic insufﬁ  ciency  •  prolonged anticoagulant effect with renal insufﬁ  ciency
• inﬂ  uenced by diet and other medications  • not  inﬂ  uenced by diet or other medications
•  requires laboratory monitoring  •  does not require laboratory monitoring
•  reversible with vitamin K  •  only partially reversible with protamine sulphate
•  no risk of heparin-induced thrombocytopenia  •  small risk of heparin-induced thrombocytopenia
•  small risk of warfarin necrosis  •  no risk of warfarin necrosis
•  no risk of osteopenia  •  small risk of osteopenia
• inexpensive  • expensiveVascular Health and Risk Management 2008:4(2) 285
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(Lee et al 2003) or Monreal protocol (Monreal et al 2004). The 
median duration of dalteparin treatment was 97 days (range 
23–243 days). The injections were administered by the patient 
(n = 46), a caregiver (n = 15) or a nurse (n = 1). Three patients 
had a clinical suspicion of recurrent VTE while off of dalteparin 
(only 1 event was conﬁ  rmed). Five patients had a minor bleed, 
of which only 1 patient stopped dalteparin (3 patients with 
bleeds were switched from the CLOT protocol to the Monreal 
protocol). Fifty patients stopped dalteparin treatment due to 
commencement of end of life pathway, and 7 stopped dalteparin 
after completion of 6 months of treatment (3 of these patients 
were clinically suspected to have recurrent VTE while off of 
treatment). The authors concluded that within the limitations 
of a case series, low-molecular-weight heparin appears to be 
effective in the setting of palliative advanced cancer.
No head to head trials comparing different types of low-
molecular-weight heparins in the treatment of cancer-related 
VTE have been published to date.
Tolerability and quality-of-life 
with dalteparin
Despite the requirement for subcutaneous injections, there is 
evidence that dalteparin is generally well tolerated by cancer 
patients. In the CLOT study, only 6% patients withdrew from 
the extended duration dalteparin arm because of the injections 
(in comparison, 4% patients withdrew from the conventional 
treatment arm) (Hull and Hull 2003). Noble and colleagues 
evaluated acceptability of low-molecular-weight heparin to 40 
palliative care cancer patients using semi-structured interviews 
(Noble and Finlay 2005). They found that patients preferred the 
freedom from blood tests that low-molecular-weight offered 
them over conventional anticoagulation with a vitamin K 
antagonist. Although many of the patients reported discomfort 
at the point of the injection, they described it as “short-lived” 
and did not label it as a signiﬁ  cant deterrent to continuing the 
injections. Acceptability of low-molecular-weight injections 
by cancer patients who do not have VTE (ie, cancer patients 
in clinical trials evaluating the potential survival advantage of 
low-molecular-weight heparin) has not been reported.
Economic implications of extended 
duration dalteparin treatment
Despite recommendations based on the results of the CLOT 
trial (Buller et al 2004), extended duration dalteparin treat-
ment of cancer-related VTE has not been widely adopted 
(pers comm). The most signiﬁ  cant barrier to adoption of 
this treatment is cost. Two different groups have recently 
conducted studies evaluating the economic implications of 
extended duration low-molecular-weight heparin treatment 
in patients with cancer-associated VTE. The ﬁ  ndings from 
these studies are outlined below (Aujesky et al 2005; 
Dranitsaris et al 2006).
Using a decision analytic model, Aujesky et al performed 
a cost-effectiveness analysis for a hypothetical cohort of 
65-year-old cancer patients receiving a 6 month course 
of low-molecular-weight heparin compared with warfarin 
(Aujesky et al 2005). This analysis, performed from the US 
societal perspective, compared anticoagulant strategies based 
on quality-adjusted life-years (QALYs) and lifetime costs. 
They determined that the low-molecular-weight heparin 
strategy achieved a higher incremental quality-adjusted life 
expectancy than warfarin (by 0.051 QALYs), but at a life-
time cost increment of US$7609 (nearly double the cost of 
warfarin). The cost of low-molecular-weight heparin in this 
model was based on 2002 US prices and on 20% of patients 
requiring nursing visits to administer injections. The authors 
concluded that LMWH is more effective than warfarin, but 
at a signiﬁ  cantly higher cost.
Dranitsaris et al performed a pharmacoeconomic analy-
sis to determine whether extended duration dalteparin in 
patients with cancer-related VTE was an economically 
reasonable alternative to warfarin (Dranitsaris et al 2006). 
This analysis, performed from the perspective of the publicly 
funded Canadian healthcare system, used the data from the 
CLOT trial to derive the overall cost of both anticoagulant 
strategies. The cost difference between the two strategies 
was used to determine incremental cost per QALY gained 
with dalteparin. They reported that the mean cost per patient 
treated with dalteparin for 6 months was CAN $4162 (2005) 
compared with warfarin at CAN$2003 (2005). The daltepa-
rin strategy produced an incremental cost of CAN$13,751 
per QALY gained which is well within the reported Cana-
dian threshold for adopting new medical interventions of 
CAN$50,000 per QALY (Laupacis et al 1992). The authors 
concluded that dalteparin is a cost-effective treatment of 
cancer-related VTE.
Conclusions
Extended duration dalteparin has been clinically proven 
to reduce the risk of recurrent VTE without signiﬁ  cantly 
increasing the risk of major bleeding in cancer patients with 
acute VTE. Additional beneﬁ  ts of dalteparin over conven-
tional anticoagulant therapy in this patient population include 
ease of administration at the time of invasive procedures 
and chemotherapy-induced thrombocytopenia, lack of 
interaction with other medications and poor diet, and lack Vascular Health and Risk Management 2008:4(2) 286
Linkins
of need for laboratory monitoring. In general, dalteparin is 
well-tolerated by cancer patients, even those with end-stage 
malignancy.
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